Navigation Links
NxStage Urges CMS to Fix Training Reimbursement to Provide Medicare Patients Greater Access to Life-Changing Home Hemodialysis Therapies
Date:9/4/2013

LAWRENCE, Mass., Sept. 4, 2013 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that it submitted public comments to the Centers for Medicare and Medicaid Services (CMS) regarding its Proposed Rule for the Changes to the End-Stage Renal Disease (ESRD) Prospective Payment System for 2014. NxStage's comments urge for CMS to correct the current insufficient and inequitable payments for home hemodialysis (HHD) training—making this life-changing modality more accessible to Medicare patients suffering from ESRD.

(Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO )

The Company calls for these changes based upon:

  • Clinical data supporting superior patient outcomes with HHD, including more frequent HHD, vs. conventional in-center dialysis;
  • Third-party surveys showing that nephrologists and other healthcare professionals would choose HHD most often for themselves if faced with ESRD, contrasting sharply with the small percentage of beneficiaries with access to HHD today;
  • A Congressional mandate for CMS to develop policy that encourages more patients to be rehabilitated and treated in the home setting; and,
  • Reliable analysis of CMS cost data showing that actual costs incurred per HHD training session ($251-261) are substantially in excess of the current add-on payment ($33.44 per session) for the required training services.

"Today's add-on payment of $33.44 per training session (intended to represent 1 hour of nursing time) is simply too low and does not adequately represent the time and effort required to ensure safe, quality care at home," said Joe Turk, President, NxStage Medical, Inc. "Given the clear and compelling benefits of home hemodialysis and the decades-old Congressional intent to encourage home dialysis and rehabilitation, it is essential that CMS update its policies for training payment to ensure beneficiary access to this modality.  It is a disservice to patients to allow this situation to remain unresolved."

A copy of the Company's submission can be found at http://www.nxstage.com/ourcompany/blog/comments-are-in

About the NxStage System One

The NxStage System One is the first and only truly portable hemodialysis system cleared for home use by the U.S. Food & Drug Administration (FDA). Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage Pureflow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, at home or on vacation. http://www.nxstage.com/.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at www.nxstage.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2013. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.


Kristen K. Sheppard, Esq.
VP, Investor Relations
ksheppard@nxstage.com


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Shows NxStage Daily Home Hemodialysis Patients More Likely to Receive Kidney Transplant
2. Former NxStage Patient Nikolas Gieske Celebrates Kidney Transplant
3. FREEDOM Study Data: Patients Experience Sustained Quality of Life Benefits with More Frequent Home Hemodialysis with the NxStage System One
4. NxStage Reports Record Revenue For The Second Quarter Of Fiscal 2012
5. NxStage to Present at the Canaccord Genuity 32nd Annual Growth Conference
6. NxStage Patient and Advocate Brian Hess Receives Prestigious Honor from American Association of Kidney Patients
7. NxStage Submits Formal Comments to CMS to Improve Patient Access to Life-changing More Frequent Home Hemodialysis Therapy
8. NxStage Names Todd M. Snell Senior Vice President of Quality Assurance, Regulatory & Clinical Affairs
9. NxStage Reports Record Revenue for the Third Quarter of Fiscal 2012
10. NxStage Announces Fourth Quarter 2012 Investor Conference Schedule
11. Robert Funari Joins NxStage Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... 2017  Sysmex America, Inc., a leading provider ... as well as middleware information systems technology, today ... quality assurance easier and more risk free than ... for the innovation that it delivers to the ... assurance processes to a new level with automated, ...
(Date:7/11/2017)... 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug delivery ... Administration (FDA) has agreed to schedule an End-of-Phase II ... trial of its oral insulin capsule ORMD-0801 in the ... met primary and secondary endpoints by indicating a statistically ...
(Date:7/10/2017)... , July 10, 2017 The Institute ... test methods, is the recipient of a VITROCELL® inhalation ... PETA International Science Consortium. The device, which is designed ... to expose human lung cells to airborne test materials ... will use the VITROCELL® system for testing combustible tobacco ...
Breaking Medicine Technology:
(Date:7/20/2017)... ... July 19, 2017 , ... A July ... lead to, or worsen, varicose veins in some patients, according to medical experts. ... certain not-so-good practices, like excessive sitting or standing, or regularly nicking yourself while ...
(Date:7/20/2017)... ... July 20, 2017 , ... “Lucky the Buffalo and Her Adventures”: a collection of heartwarming ... Edward Bieniek. Edward Steven Bieniek Jr. was born in Toledo, Ohio. He attended ... com tech. He is married to a brilliant woman with a caring heart named ...
(Date:7/18/2017)... ... 2017 , ... Cognition Corporation , a software company ... of its “From the Helm” Webinar Series. , These sessions will focus ... CEO, the half-hour public webinars will take an in-depth look at applying usability ...
(Date:7/18/2017)... ... ... The results of an international clinical trial, led in part by a UC Davis School ... dystrophy holds promise for a subgroup of patients. , In a paper just published online ... study sites in 18 countries describe the clinical benefit of using the drug ataluren for ...
(Date:7/18/2017)... ... ... An inventor from Anacortes, Wash., knows the difficulties and indignity of not being ... I suffer from anxiety and vertigo on top of that," she said, "so I ... meets that need. , This device enables a woman in menopause to cool off ...
Breaking Medicine News(10 mins):